Could CAR T-Cells halt progressive MS? early trial launches
NCT ID NCT07139743
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called obe-cel, a type of cell therapy (CAR T-cell), for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. The main goal is to see if it's safe, but researchers will also look for any signs it might slow the disease. Only 18 adults aged 18 to 60 will receive a single infusion of obe-cel after a short course of chemotherapy, and they will be followed for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obe-cel (a CAR T-cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for people with progressive multiple sclerosis that hasn't responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 18 people, so it's mainly checking safety. The treatment may not work, and there are risks from the chemotherapy given beforehand and potential side effects from the cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrooke's Hospital
RECRUITINGCambridge, United Kingdom
Contact
-
Hospital Universitari i Politecnic La Fe de Valencia
RECRUITINGValencia, Spain
Contact
-
Hospital Universitario Vall d'Hebron - PPDS
ACTIVE_NOT_RECRUITINGBarcelona, Spain
-
Royal Hallamshire Hospital
RECRUITINGSheffield, United Kingdom
Contact
-
Stanford University
NOT_YET_RECRUITINGRedwood City, California, 94063, United States
Contact
-
The National Hospital for Neurology & Neurosurgery
RECRUITINGLondon, United Kingdom
Contact Email: •••••@•••••
Contact
-
Western General Hospital Edinburgh - PPDSE Edinburgh
RECRUITINGEdinburgh, United Kingdom
Contact